CYTK Quote, Financials, Valuation and Earnings

Biogen has a net margin of -886.28% compared to Cytokinetics's net margin of 10.87%. Cytokinetics's return on equity of -- beat Biogen's return on equity of 10.33%.

Cytokinetics has a consensus price target of $78.95, signalling upside risk potential of 104.27%. On the other hand Biogen has an analysts' consensus of $197.16 which suggests that it could grow by 71.19%. Given that Cytokinetics has higher upside potential than Biogen, analysts believe Cytokinetics is more attractive than Biogen.

Cytokinetics has a beta of 0.938, which suggesting that the stock is 6.231% less volatile than S&P 500. In comparison Biogen has a beta of 0.057, suggesting its less volatile than the S&P 500 by 94.303%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are smaller than Biogen quarterly revenues of $2.5B. Cytokinetics's net income of -$150M is lower than Biogen's net income of $266.7M. Notably, Cytokinetics's price-to-earnings ratio is -- while Biogen's PE ratio is 10.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 233.78x versus 1.74x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Edgewise Therapeutics has a net margin of -886.28% compared to Cytokinetics's net margin of --. Cytokinetics's return on equity of -- beat Edgewise Therapeutics's return on equity of --.

Cytokinetics has a consensus price target of $78.95, signalling upside risk potential of 104.27%. On the other hand Edgewise Therapeutics has an analysts' consensus of $42.78 which suggests that it could grow by 274.59%. Given that Edgewise Therapeutics has higher upside potential than Cytokinetics, analysts believe Edgewise Therapeutics is more attractive than Cytokinetics.

Cytokinetics has a beta of 0.938, which suggesting that the stock is 6.231% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are larger than Edgewise Therapeutics quarterly revenues of --. Cytokinetics's net income of -$150M is lower than Edgewise Therapeutics's net income of -$39.7M. Notably, Cytokinetics's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 233.78x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -886.28% compared to Cytokinetics's net margin of 32.59%. Cytokinetics's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

Cytokinetics has a consensus price target of $78.95, signalling upside risk potential of 104.27%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.63 which suggests that it could grow by 37.99%. Given that Cytokinetics has higher upside potential than Eli Lilly and, analysts believe Cytokinetics is more attractive than Eli Lilly and.

Cytokinetics has a beta of 0.938, which suggesting that the stock is 6.231% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.74% to investors and pays a quarterly dividend of $1.50 per share. Cytokinetics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cytokinetics quarterly revenues are $16.9M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Cytokinetics's net income of -$150M is lower than Eli Lilly and's net income of $4.4B. Notably, Cytokinetics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 62.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 233.78x versus 14.70x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -886.28% compared to Cytokinetics's net margin of -747.33%. Cytokinetics's return on equity of -- beat Sage Therapeutics's return on equity of -63.59%.

Cytokinetics has a consensus price target of $78.95, signalling upside risk potential of 104.27%. On the other hand Sage Therapeutics has an analysts' consensus of $8.10 which suggests that it could grow by 13.15%. Given that Cytokinetics has higher upside potential than Sage Therapeutics, analysts believe Cytokinetics is more attractive than Sage Therapeutics.

Cytokinetics has a beta of 0.938, which suggesting that the stock is 6.231% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.477, suggesting its less volatile than the S&P 500 by 52.304%.

Cytokinetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cytokinetics pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Cytokinetics quarterly revenues are $16.9M, which are larger than Sage Therapeutics quarterly revenues of $12.8M. Cytokinetics's net income of -$150M is lower than Sage Therapeutics's net income of -$95.8M. Notably, Cytokinetics's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cytokinetics is 233.78x versus 10.55x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.